Study on the preventive effect of the gelomyrtol forte from secretory otitis media in patients with nasopharyngeal carcinoma after radiotherapy / 临床耳鼻咽喉头颈外科杂志

OBJECTIVE@#To observed the prevention efficacy of secretory otitis media after radiation therapy by the Myrtol Standardized Enteric Coated Soft Capsules.@*METHOD@#Sixty patients with nasopharyngeal carcinoma who Diagnosis without secretory otitis media before radiation therapy were divided into experimental group and control group, 30 cases in each group. After the start of radiation therapy ,the experimental group patients oral the Myrtol Standardized Enteric Coated Soft Capsules, each 0.3 g, 3 times a day, 7 days a course of treatment, oral the medication three months, the patients in the control group received no treatment. 3 months and 6 months after the end of radiation therapy, whether there is a difference comparison of experimental group and the control group in symptoms, signs, pure tone audiometry and tympanogram change.@*RESULT@#Seventeen patients (18 ears) (56.67%, 17/30) in the control group were suffering from secretory otitis media, 7 patients (7 ears) (23.33%, 7/30) in the experimental group were suffering from secretory otitis media. The difference between the two groups was statistically significant (P 0.05). 3 months after radiation therapy,the gas conductive hearing threshold of the experimental group is (25.6 +/- 3.0) dB HL, but the data in the control group is (40.7 +/- 5.0) dB HL. The difference between the two groups was statistically significant (P < 0.01).@*CONCLUSION@#Patients with nasopharyngeal carcinoma oral the the Myrtol Standardized Enteric Coated Soft Capsules before radiation therapy can effectively reduce the incidence of secretory otitis media after radiotherapy, it can prevent the occurrence of secretory otitis media.

Antiatherogenic effect of piperlonguminine on experimental atherosclerosis in rabbits / 中国中药杂志

<p><b>OBJECTIVE</b>To investigate of antiatherogenic effect and possible mechanisms of piper longuminine.</p><p><b>METHOD</b>The atherosclerotic model was established by the hypercholesterol feeding rabbits. Male Mew Zealand rabbits were randomly divided into five groups: normal group, model group, the high-dose (5 mg x kg(-1) x d(-1)) and low-dose (2.5 mg x kg(-1) x d(-1) group of piperlonguminine, and simvastatin group (5 mg x kg(-1) x d(-1)). All the rabbits were fed for 60 days. Blood samples were taken from the ear edge vein of rabbits in the day before the experiment, and in the days of 20, 40 and 60 days after the experiment, respectively. All the rabbits were fasted for at least twelve hours before the blood was taken. The blood serum were analyzed for total cholesterol (TC), triglyceride (TG), low density lipoprotein cholesterol (LDL-C) and high-density lipoprotein cholesterol (HDL-C). The blood serum of the 60th day were also analyzed for superoxide dismutase (SOD), malondialdehyde (MDA) and nitric oxide (NO). At last, the pathological observation of aorta and heart samples were carried out.</p><p><b>RESULT</b>Compared with those in model group, the TC, TG and LDL-C levels were reduced (P < 0.05) and the HDL-C was raised in the piperlonguminine group; also, the serum SOD and NO level was raised (P < 0.05), MDA level was reduced in the piperlonguminine group (P < 0.05). Area percentage of aorta plaque was reduced (P < 0.01) in the piperlonguminine group. The aorta and heart injury was abated and coronary artery angusty extent was markedly abatement (P < 0.01). The results of observation through transmission electron microscope (TEM) indicated that the fine structure of aortal pathological degree was markedly abated.</p><p><b>CONCLUSION</b>The piperlonguminine could inhibit the atherogenesis formation and development, which might be due to regulating the lipid metabolism and enhancing the antioxidation.</p>